$32.51
1.93% yesterday
Nasdaq, Sep 27, 10:02 pm CET
ISIN
US87650L1035
Symbol
TARS
Sector
Industry

Tarsus Pharmaceuticals Inc Stock price

$32.51
+5.52 20.45% 1M
-2.06 5.96% 6M
+12.26 60.54% YTD
+16.72 105.89% 1Y
+9.52 41.41% 3Y
+16.51 103.19% 5Y
+16.51 103.19% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.64 1.93%
ISIN
US87650L1035
Symbol
TARS
Sector
Industry

Key metrics

Market capitalization $1.26b
Enterprise Value $1.01b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 12.11
P/S ratio (TTM) P/S ratio 15.13
P/B ratio (TTM) P/B ratio 5.00
Revenue growth (TTM) Revenue growth 566.99%
Revenue (TTM) Revenue $83.37m
EBIT (operating result TTM) EBIT $-156.37m
Free Cash Flow (TTM) Free Cash Flow $-125.48m
Cash position $323.58m
EPS (TTM) EPS $-4.48
P/E forward negative
P/S forward 7.68
EV/Sales forward 6.15
Short interest 26.69%
Show more

Is Tarsus Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Tarsus Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Tarsus Pharmaceuticals Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Tarsus Pharmaceuticals Inc forecast:

Buy
88%
Hold
13%

Financial data from Tarsus Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
83 83
567% 567%
100%
- Direct Costs 6.62 6.62
461% 461%
8%
77 77
578% 578%
92%
- Selling and Administrative Expenses 182 182
202% 202%
218%
- Research and Development Expense 50 50
9% 9%
60%
-155 -155
64% 64%
-186%
- Depreciation and Amortization 1.23 1.23
23% 23%
1%
EBIT (Operating Income) EBIT -156 -156
63% 63%
-188%
Net Profit -150 -150
65% 65%
-180%

In millions USD.

Don't miss a Thing! We will send you all news about Tarsus Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tarsus Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
2 days ago
IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Aziz Mottiwala, Chief Commercial Officer, will participate in a virtual fireside chat at the UBS Virtual Ophthalmology Day 2024 ta...
Positive
Seeking Alpha
7 days ago
Tarsus Pharmaceuticals, Inc.'s Xdemvy, the first FDA-approved treatment for demodex blepharitis, has shown significant efficacy and rapid revenue growth, with $40.8M revenue in Q2 2024. The company is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 results and ongoing FDA discussions. Strong financials with $323M in cash reserves, a healthy current r...
Neutral
GlobeNewsWire
about one month ago
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will...
More Tarsus Pharmaceuticals Inc News

Company Profile

Tarsus Pharmaceuticals, Inc. develops and manufactures drug treatments for Blepharitis. The company focuses on treatment of Blepharitis, which is a common ocular condition, characterized by inflammation of the eyelid, which can impact the anterior or posterior lid or both. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Head office United States
CEO Bobak Azamian
Employees 244
Founded 2017
Website tarsusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today